Condition
Non-arteritic Ischemic Optic Neuropathy
Total Trials
6
Recruiting
1
Active
1
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
40%
2 of 5 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Completed5
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT03011541Not ApplicableRecruiting
Stem Cell Ophthalmology Treatment Study II
NCT05305079CompletedPrimary
NA-AION Risk Factors: New Perspectives
NCT03758118Not ApplicableCompletedPrimary
Citicoline in Non-Arteritic Ischemic Optic Neuropathy
NCT06031350CompletedPrimary
Peripapillary and Macular Vascular Changes of Unilateral Anterior Ischemic Optic Neuropathy: An Optical Coherence Tomography Angiography Study
NCT02045212Phase 2CompletedPrimary
Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
NCT01614158CompletedPrimary
Assessment of Visual Field-related Endpoints in Patients With Non-arteritic Ischemic Optic Neuropathy
Showing all 6 trials